<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293396</url>
  </required_header>
  <id_info>
    <org_study_id>ENM-DA-008</org_study_id>
    <secondary_id>2008-008486-35</secondary_id>
    <nct_id>NCT01293396</nct_id>
  </id_info>
  <brief_title>Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids</brief_title>
  <acronym>HUCKEPACK2</acronym>
  <official_title>Comparison of the Impact of Biphasic Insulin Aspart 30 (BiAsp 30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate meal-related treatment with either premixed Insulin&#xD;
      Aspart 30, Aspart 70 and Aspart with regard to postprandial glucose, triglyceride and free&#xD;
      fatty acids excursions after a standard breakfast and lunch.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whereas the effects of each of the established types of insulin (remixed Insulin Aspart 30,&#xD;
      Aspart 70 and Aspart) have been shown before, their specific glucose and lipid lowering&#xD;
      capacities have so far not been investigated in a simulated physiological situation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Over Basal for Postprandial Glucose From 0 to 600min</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Area over basal for postprandial glucose from 0 (Fasting glucose, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Over Basal for Postprandial Triglycerides</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Area over basal for postprandial triglycerides from 0 (Fasting triglycerides, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Glucose Increase</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Maximum glucose increase from baseline to 600min after baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Triglyceride Increase</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Maximum trigylceride increase from Baseline to 600min after Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Over Basal for Postprandial Insulin</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Area over basal for postprandial insulin from 0 (Fasting insulin, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Over Basal for Postprandial C-peptide</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
    <description>Area over basal for postprandial c-peptide from 0 (Fasting c-peptide, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Biphasic Insulin Aspart 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biphasic Insulin Aspart 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Patients received insulin aspart before breakfast and before lunch.</description>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <other_name>Novorapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart 30</intervention_name>
    <description>Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
    <arm_group_label>Biphasic Insulin Aspart 30</arm_group_label>
    <other_name>Novomix 30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart 70</intervention_name>
    <description>Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
    <arm_group_label>Biphasic Insulin Aspart 70</arm_group_label>
    <other_name>Novomix 70</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type-II Diabetes&#xD;
&#xD;
          -  BMI &gt; 27 kg/m2&#xD;
&#xD;
          -  age 35 to 75 years&#xD;
&#xD;
          -  HbA1c &lt; 8.5%&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  treatment with pre-mixed insulin&#xD;
&#xD;
          -  stabile dose of insulin for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type-I Diabetes mellitus&#xD;
&#xD;
          -  HbA1c &gt; 8.5 %&#xD;
&#xD;
          -  Serum Creatinine &gt; 1.7 mg/dl&#xD;
&#xD;
          -  Alaninaminotranferase or Aspartataminotransferase &gt; 3x Upper Limit of Normal&#xD;
&#xD;
          -  treatment with sulfonylurea or gliptins&#xD;
&#xD;
          -  treatment with glitazones&#xD;
&#xD;
          -  manifest clinical infections&#xD;
&#xD;
          -  treatment with glucocorticoids or antipsychotic drugs&#xD;
&#xD;
          -  psychiatric diseases&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  myocardial infarction or stroke within the previous 3 months&#xD;
&#xD;
          -  surgery within the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, 8036 Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department for Internal Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <results_first_submitted>March 17, 2020</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin aspart 30</keyword>
  <keyword>insulin aspart 70</keyword>
  <keyword>insulin aspart</keyword>
  <keyword>postprandial glucose and lipid metabolism</keyword>
  <keyword>consecutive mixed meals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 patients were screened and in total 20 randomizations were performed. After randomization 20 randomized subjects finished all three study visits.</recruitment_details>
      <pre_assignment_details>All subjects received all of the three insulins within various sequences in a randomized order. Randomisation lists for the insulin sequence were provided by a researcher otherwise not involved in the clinical trial performance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Participants were randomized to each intervention and re-randomized to the remaining interventions after each washout period.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Participants were randomized to each intervention and re-randomized to the remaining interventions after each washout period</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Participants were randomized to each intervention and re-randomized to the remaining interventions after each washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash Out Period 1 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash Out Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>20 patients with type 2 diabetes receive insulin aspart, premixed biphasic insulin 30 and premixed biphasic insulin aspart 70 in randomized order.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Measure Type: Count of Participants Unit of measure: participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Over Basal for Postprandial Glucose From 0 to 600min</title>
        <description>Area over basal for postprandial glucose from 0 (Fasting glucose, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Over Basal for Postprandial Glucose From 0 to 600min</title>
          <description>Area over basal for postprandial glucose from 0 (Fasting glucose, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
          <units>mg*/min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591" spread="681"/>
                    <measurement group_id="O2" value="220" spread="617"/>
                    <measurement group_id="O3" value="197" spread="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Over Basal for Postprandial Triglycerides</title>
        <description>Area over basal for postprandial triglycerides from 0 (Fasting triglycerides, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Over Basal for Postprandial Triglycerides</title>
          <description>Area over basal for postprandial triglycerides from 0 (Fasting triglycerides, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" spread="342"/>
                    <measurement group_id="O2" value="358" spread="544"/>
                    <measurement group_id="O3" value="412" spread="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Glucose Increase</title>
        <description>Maximum glucose increase from baseline to 600min after baseline</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Glucose Increase</title>
          <description>Maximum glucose increase from baseline to 600min after baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.25" spread="57.85"/>
                    <measurement group_id="O2" value="55.95" spread="42.44"/>
                    <measurement group_id="O3" value="60.25" spread="40.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Triglyceride Increase</title>
        <description>Maximum trigylceride increase from Baseline to 600min after Baseline</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Triglyceride Increase</title>
          <description>Maximum trigylceride increase from Baseline to 600min after Baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" spread="342"/>
                    <measurement group_id="O2" value="358" spread="544"/>
                    <measurement group_id="O3" value="412" spread="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Over Basal for Postprandial Insulin</title>
        <description>Area over basal for postprandial insulin from 0 (Fasting insulin, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Over Basal for Postprandial Insulin</title>
          <description>Area over basal for postprandial insulin from 0 (Fasting insulin, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
          <units>µU*min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.2" spread="149.7"/>
                    <measurement group_id="O2" value="141.2" spread="155.3"/>
                    <measurement group_id="O3" value="128.6" spread="106.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Over Basal for Postprandial C-peptide</title>
        <description>Area over basal for postprandial c-peptide from 0 (Fasting c-peptide, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
        <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 minutes post-dose (daily study start)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biphasic Insulin Aspart 30</title>
            <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart 70</title>
            <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
          </group>
          <group group_id="O3">
            <title>Insulin Aspart</title>
            <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Over Basal for Postprandial C-peptide</title>
          <description>Area over basal for postprandial c-peptide from 0 (Fasting c-peptide, measured at daily study start) to 600 min (after breakfast) Area over basal is calculated according to the trapezoidal rule.</description>
          <units>mg*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="14.1"/>
                    <measurement group_id="O2" value="12.8" spread="11.5"/>
                    <measurement group_id="O3" value="13.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Biphasic Insulin Aspart 30</title>
          <description>Insulin Aspart 30: Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
        </group>
        <group group_id="E2">
          <title>Biphasic Insulin Aspart 70</title>
          <description>Insulin Aspart 70: Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
        </group>
        <group group_id="E3">
          <title>Insulin Aspart</title>
          <description>Insulin Aspart: Patients received insulin aspart before breakfast and before lunch.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Mild Hypo</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Hypoglycaemic Event</sub_title>
                <description>Hypoglycaemic events blood glucose levels &lt;70mg/dL</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Moderate Hypo">Moderate Hypoglycaemic Event</sub_title>
                <description>Hypogylcaemic Event &lt;54mg/dL</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Norbert Tripolt</name_or_title>
      <organization>Medical University of Graz</organization>
      <phone>0316385 ext 78038</phone>
      <email>norbert.tripolt@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

